Diabetic Neuropathic Pain - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/qm4xdv/diabetic) has announced the addition of the "Diabetic Neuropathic Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca - Eli Lilly and Company - BioDelivery Sciences - Daiichi Sankyo - Acorda Therapeutics - Astellas Pharma - Glenmark Pharmaceuticals - KunWha Pharmaceutical - Mertiva - Grunenthal - Kyorin Pharmaceutical - Bial - Lohocla Research - Relmada Therapeutics - Sphaera Pharma - Immune Pharmaceuticals - AbbVie - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/qm4xdv/diabetic
IMNP: 1.89 (+0.02), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), ACOR: 39.14 (+0.74)
Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/znzbgg/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - Aastrom Biosciences - Johnson & Johnson - AstraZeneca - Athersys - GlaxoSmithKline - Gilead Sciences - Merck & Co - Bioheart - Neurocrine Biosciences - Acorda Therapeutics - Les Laboratoires Servier - Bayer - Celladon - IntelGenx - Mesoblast - Palatin Technologies - Cardio3 BioSciences - La Jolla Pharmaceutical - Mast Therapeutics - NeoStem - Cytomedix - Torrent Pharmaceuticals - Juventas Therapeutics - Protemix Corporation - AngioDesign - Cardioxyl Pharmaceuticals - Innopharmax - QUANTUM GENOMICS - ARCA biopharma For more information visit http://www.researchandmarkets.com/research/zn...tive_heart
JNJ: 104.59 (+0.31), NBIX: 21.33 (+0.09), MSTX: 0.46 (unch), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), PTN: 0.71 (+0.04), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), ACOR: 39.14 (+0.74)
Postherpetic Neuralgia - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/489mg3/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - Allergan - Acorda Therapeutics - Daewoong Pharmaceutical - Pfizer - Purdue Pharma - Teva Pharmaceutical Industries - Nuvo Research Inc. - Arcion Therapeutics, Inc. - NeurAxon, Inc. - Winston Pharmaceuticals, Inc. - Bial - Portela & Ca, S.A. - Spinifex Pharmaceuticals Pty Limited - Relmada Therapeutics, Inc. - Aestus Therapeutics, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Immune Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/48...stherpetic
AGN: 210.12 (+0.95), TEVA: 57.09 (+0.33), IMNP: 1.89 (+0.02), BMY: 59.15 (-0.01), ACOR: 39.14 (+0.74)
3 Companies Growing Faster Than MannKind Corporation
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 17, 6:03AM CST
Source: MannKind. MannKind shareholders have had quite the year. After more than doubling in the first half of the year, shares have since given back all of their gains and sit essentially unchanged. Despite the stalemate, MannKind could be on...
AKRX: 36.47 (+0.43), ALXN: 181.96 (+3.09), ACOR: 39.14 (+0.74), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)
Acorda's Ampyra in Phase III for Post-Stroke Walking Deficit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 4:46PM CST
Acorda (ACOR) has commenced a phase III study on Ampyra for the treatment of post-stroke walking deficits.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), AMGN: 160.67 (+3.15), ACOR: 39.14 (+0.74)
Acorda starts label expansion study for dalfampridine
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 10:52AM CST
ACOR: 39.14 (+0.74)
Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits
Business Wire - Mon Dec 15, 6:01AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the first patient has been enrolled in a Phase 3 clinical trial of dalfampridine for the treatment of post-stroke walking deficits (PSWD).
ACOR: 39.14 (+0.74)
Peripheral Neuropathic Pain - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/zfw6sm/peripheral) has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H2 2013" report to their offering. 'Peripheral Neuropathic Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Neuropathic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain. Peripheral Neuropathic Pain - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Peripheral Neuropathic Pain. - A review of the Peripheral Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Peripheral Neuropathic Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Bristol-Myers Squibb Company - Sanofi - Acorda Therapeutics, Inc. - Pfizer Inc. - Avanir Pharmaceuticals, Inc. - Grunenthal GmbH - Sphaera Pharma Pvt. Ltd. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/zfw6sm/peripheral
PFE: 31.42 (-0.03), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ACOR: 39.14 (+0.74)
Cerebral Palsy - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdwf83/cerebral_palsy) has announced the addition of the "Cerebral Palsy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cerebral Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Palsy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cerebral Palsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cerebral Palsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Allergan - Acorda Therapeutics, Inc. - Neuralstem, Inc. - CHA Bio & Diostech Co., Ltd. - K-Stemcell Co., Ltd. - Cell Cure Neurosciences, Ltd. - Cellular Biomedicine Group, Inc. For more information visit http://www.researchandmarkets.com/research/zd...bral_palsy
AGN: 210.12 (+0.95), ACOR: 39.14 (+0.74), CBMG: 12.98 (+0.19), CUR: 2.70 (+0.07)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 31.32 (+0.26), ADMS: 16.10 (+1.45), TEVA: 57.09 (+0.33), ACOR: 39.14 (+0.74), PRTA: 20.14 (+1.41), NDRM: 5.90 (-0.19)
Acorda Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson's Disease
Business Wire - Wed Dec 10, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the first patient has been enrolled in a Phase 3 study of CVT-301 for the treatment of OFF episodes in Parkinson's disease (PD). OFF episodes are characterized by a re-emergence of PD symptoms such as tremor, muscle stiffness and impaired ability to move.
ACOR: 39.14 (+0.74)
Seizures Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Mon Dec 08, 6:30PM CST
The report "Seizures Pipeline Review H2 2014" is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/seizures-pip...eport.html .
PFE: 31.42 (-0.03), ACOR: 39.14 (+0.74), CNCE: 11.76 (+0.11), NVS: 93.91 (+0.66)
Acorda Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Tue Dec 02, 5:32AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Michael Rogers, Chief Financial Officer, and Andrew Blight, Chief Scientific Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 2 at 11:00am.
ACOR: 39.14 (+0.74)
Is Acorda Therapeutics (ACOR) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 7:31AM CST
Acorda Therapeutics is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
ACOR: 39.14 (+0.74)
Cynapsus Or Acorda - Whose Market Is It For Parkinson's Disease?
Michael Hagan - Seeking Alpha - Tue Nov 25, 7:41AM CST
In the past several weeks, there has been an increase in stories appearing on companies that are involved in Parkinson's disease research. Acorda's (NASDAQ: ACOR ) buyout of Civitas Therapeutics, NeuroDerm's (NASDAQ: NDRM ) (IPO) and the...
ACOR: 39.14 (+0.74), NDRM: 5.90 (-0.19)
Acorda Therapeutics Earnings In Retrospect: Down 7.4% in the Last 18 Days (ACOR)
Comtex SmarTrend(R) - Mon Nov 17, 3:28PM CST
18 days ago, on October 30th, 2014, Acorda Therapeutics (NASDAQ:ACOR) reported its earnings. Analysts, on average, expected earnings of $0.26 per share on sales of $94.6 million. The company actually reported EPS of $0.65 on sales of $106.0 million, beating EPS estimates by $0.39 and beating revenue estimates by $11.4 million. Since the company's report, shares of Acorda Therapeutics have fallen from $36.15 to $33.47, representing a loss of 7.4% in the past 18 days.
ACOR: 39.14 (+0.74)
Acorda Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
Business Wire - Fri Nov 14, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Andrew Blight, Chief Scientific Officer, will present at the Jefferies 2014 Global Healthcare Conference in London on Wednesday, November 19 at 9:20am GMT.
ACOR: 39.14 (+0.74)
Acorda Growth Is Expected To Stall
Stock Traders Daily - at Seeking Alpha - Wed Nov 12, 10:38AM CST
ACOR: 39.14 (+0.74)
Acorda Therapeutics to Present at the Stifel 2014 Healthcare Conference
Business Wire - Wed Nov 12, 6:01AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Ron Cohen, M.D., President and Chief Executive Officer will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 at 1:50pm ET.
ACOR: 39.14 (+0.74)
Acorda Therapeutics to Present at the Credit Suisse 2014 Healthcare Conference
Business Wire - Tue Nov 04, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Michael Rogers, Chief Financial Officer will present at the Credit Suisse 2014 Healthcare Conference in Phoenix on Tuesday, November 11 at 3:30pm MT.
ACOR: 39.14 (+0.74)